Bb Biotech Ag Stock Net Income
BBZA Stock | EUR 39.95 0.05 0.12% |
BB Biotech AG fundamentals help investors to digest information that contributes to BB Biotech's financial success or failures. It also enables traders to predict the movement of BBZA Stock. The fundamental analysis module provides a way to measure BB Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BB Biotech stock.
BBZA |
BB Biotech AG Company Net Income Analysis
BB Biotech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current BB Biotech Net Income | (357.81 M) |
Most of BB Biotech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BB Biotech AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition |
Based on the recorded statements, BB Biotech AG reported net income of (357.81 Million). This is 204.84% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all Germany stocks is 162.67% higher than that of the company.
BBZA Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BB Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BB Biotech could also be used in its relative valuation, which is a method of valuing BB Biotech by comparing valuation metrics of similar companies.BB Biotech is currently under evaluation in net income category among its peers.
BBZA Fundamentals
Return On Equity | -0.12 | |||
Return On Asset | -0.008 | |||
Current Valuation | 226.69 M | |||
Shares Outstanding | 54.85 M | |||
Shares Owned By Insiders | 1.70 % | |||
Shares Owned By Institutions | 7.93 % | |||
Price To Earning | 4.19 X | |||
Price To Book | 1.27 X | |||
Price To Sales | 800,360 X | |||
Revenue | (351.23 M) | |||
Gross Profit | 4 K | |||
Net Income | (357.81 M) | |||
Book Value Per Share | 48.98 X | |||
Cash Flow From Operations | (94.79 M) | |||
Earnings Per Share | (6.58) X | |||
Target Price | 59.87 | |||
Number Of Employees | 10 | |||
Beta | 0.87 | |||
Market Capitalization | 2.98 B | |||
Total Asset | 3.05 B | |||
Annual Yield | 0.05 % | |||
Net Asset | 3.05 B | |||
Last Dividend Paid | 2.85 |
About BB Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BB Biotech AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BB Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BB Biotech AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in BBZA Stock
BB Biotech financial ratios help investors to determine whether BBZA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BBZA with respect to the benefits of owning BB Biotech security.